HUYA Bioscience International names new vice president, Commercial Planning.
M2 PHARMA-December 16, 2015-HUYA Bioscience International names new vice president, Commercial Planning
(C)2015 M2 COMMUNICATIONS
HUYA Bioscience International, a company involved in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China, has named Scott Garrett MBA as its vice president, Commercial Planning, it was reported yesterday.
Garrett has more than 20 years of commercial experience in both drugs and devices for oncology and cardiovascular disease with companies such as Celladon, Mallinckrodt, Gilead, Johnson and Johnson, Boston Scientific and Nycomed Amersham (now GE Healthcare). His prior responsibilities include sales and marketing, commercial planning, product launch, healthcare economics, reimbursement, advocacy development, life cycle management, and business development for brands such as CERETEC, TAXUS, NATRECOR, RANEXA and OFIRMEV.
Mireille Gillings PhD, CEO of HUYA, said, 'Scott's commercial experience in oncology and cardiovascular disease will play a key role as HUYA transitions from a development to a commercial-stage company. We welcome him to the HUYA senior management team, where he will assume responsibility for the Company's increasing commercial focus.'
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 16, 2015|
|Previous Article:||Trident Brands names new special advisor to Brain Armor.|
|Next Article:||Bristol-Myers Squibb signs collaboration agreement with the University of California.|